Recent Finacing
Recent Raise
TIXiMED is a clinical-stage pharmaceutical company developing TIX100, an oral TXNIP inhibitor intended to promote beta cell survival and function in type 1 diabetes.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investor
See the team members at TIXiMED.
